• SPX
  • $5,733.37
  • 0.36 %
  • $20.68
  • DJI
  • $41,869.21
  • 0.18 %
  • $74.61
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,157.09
  • -0.33 %
  • -$27.15
  • IXIC
  • $18,283.09
  • 0.57 %
  • $103.10
ProQR Therapeutics N.V. (PRQR) Stock Price, News & Analysis

ProQR Therapeutics N.V. (PRQR) Stock Price, News & Analysis

Currency in USD Disclaimer

$3.61

-$0.02

(-0.55%)

Day's range
$3.56
Day's range
$3.7
50-day range
$1.65
Day's range
$4.62
  • Country: NL
  • ISIN: NL0010872495
52 wk range
$1.18
Day's range
$4.62
  • CEO: Mr. Daniel Anton de Boer
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -2.30
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (PRQR)
  • Company ProQR Therapeutics N.V.
  • Price $3.61
  • Changes Percentage (-0.55%)
  • Change -$0.02
  • Day Low $3.56
  • Day High $3.70
  • Year High $4.62

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/06/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $3.75
  • High Stock Price Target $5.00
  • Low Stock Price Target $2.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.36
  • Trailing P/E Ratio -5.14
  • Forward P/E Ratio -5.14
  • P/E Growth -5.14
  • Net Income $-27,542,618

Income Statement

Quarterly

Annual

Latest News of PRQR

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.